Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug

Law360, New York (June 21, 2012, 7:39 PM ET) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent for the medication.

BMS said in its complaint that unless Sandoz is blocked from carrying through with plans to make entecavir — the active ingredient in Baraclude — which it submitted in an abbreviated new drug application to the U.S. Food and Drug Administration, the generic maker would infringe BMS’s U.S. Patent Number...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required